Humalog 100 units/ml, solution for injection in vial

  • Name:

    Humalog 100 units/ml, solution for injection in vial

  • Company:
    info
  • Active Ingredients:

    Insulin lispro

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 24/09/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 16/9/2020

Click on this link to Download PDF directly

Eli Lilly and Company (Ireland) Limited

Eli Lilly and Company (Ireland) Limited

Company Products

Medicine NameActive Ingredients
Medicine Name ABASAGLAR 100 units/mL KwikPen solution for injection in a pre-filled pen Active Ingredients Insulin glargine
Medicine Name Adcirca 20 mg film-coated tablets Active Ingredients Tadalafil
Medicine Name Alimta 100 mg, 400 mg powder for concentrate for solution for infusion Active Ingredients Pemetrexed disodium
Medicine Name Cialis 10mg film-coated tablets Active Ingredients Tadalafil
Medicine Name Cialis 20mg film-coated tablets Active Ingredients Tadalafil
Medicine Name Cialis 5mg film-coated tablets Active Ingredients Tadalafil
Medicine Name Cymbalta 30 mg, 60 mg hard gastro-resistant capsules Active Ingredients duloxetine hydrochloride
Medicine Name Cyramza 10 mg/ml concentrate for solution for infusion Active Ingredients Ramucirumab
Medicine Name Forsteo 20 micrograms/80 microliters solution for injection in pre-filled pen Active Ingredients Teriparatide
Medicine Name Humalog 100 units/ml Junior KwikPen, solution for injection in a pre-filled pen Active Ingredients Insulin lispro
Medicine Name Humalog 100 units/ml Kwikpen soluton for injection Active Ingredients Insulin lispro
Medicine Name Humalog 100 units/ml, solution for injection in cartridge (3ml) (insulin lispro) Active Ingredients Insulin lispro
Medicine Name Humalog 100 units/ml, solution for injection in vial Active Ingredients Insulin lispro
Medicine Name Humalog 200 Units/ml KwikPen, solution for injection in pre-filled pen Active Ingredients Insulin lispro
Medicine Name Humalog Mix25 100 units/ml Kwikpen suspension for injection Active Ingredients Insulin lispro
Medicine Name Humalog Mix25 100 units/ml suspension for injection in cartridge Active Ingredients Insulin lispro
Medicine Name Humalog Mix50 100 units/ml Kwikpen suspension for injection Active Ingredients Insulin lispro
Medicine Name Humalog Mix50 100 units/ml suspension for injection in cartridge Active Ingredients Insulin lispro
Medicine Name Humulin I (Isophane), 100IU/ml suspension for injection in cartridge Active Ingredients Insulin human
Medicine Name Humulin I (Isophane), 100IU/ml suspension for injection in vial Active Ingredients Human Insulin
Medicine Name Humulin I KwikPen 100 IU/ml suspension for injection Active Ingredients Human Insulin
Medicine Name Humulin M3 (Mixture 3), 100IU/ml suspension for injection in cartridge Active Ingredients Insulin human
Medicine Name Humulin M3 (Mixture 3), 100IU/ml suspension for injection in vial Active Ingredients Insulin human
Medicine Name Humulin M3 KwikPen 100 IU/ml suspension for injection Active Ingredients Human Insulin
Medicine Name Humulin S (soluble), 100IU/ml solution for injection in cartridge Active Ingredients Insulin human
1 - 0 of 38 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 24 September 2020 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

Changes

Added (underline) deleted (strikethrough)

 

Section 2

What you need to know before you use Humalog  

Warnings and precautions

…..

Skin changes at the injection site

The injection site should be rotated to prevent skin changes such as lumps under the skin. The insulin may not work very well if you inject into a lumpy area (See How to use Humalog). Contact your doctor if you are currently injecting into a lumpy area before you start injecting a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose.

 

 4.         Possible side effects

…..

Lipodystrophy (thickening or pitting of the skin) is uncommon (³ 1/1,000 to <1/100). If you notice your skin thickening or pitting at the injection site, tell your doctor. If you inject insulin too often at the same place, the fatty tissue may either shrink (lipoatrophy) or thicken (lipohypertrophy). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis). The insulin may not work very well if you inject into a lumpy area. Change the injection site with each injection to help prevent these skin changes.

 

6.             Contents of the pack and other information

…..

This leaflet was last revised in September 2020.

Updated on 16 September 2020 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Changes

Added (underline) deleted (strikethrough)

4.       CLINICAL PARTICULARS

4.2   Posology and method of administration

……….

Method of administration

………

Use of injection sites should be rotated so that the same site is not used more than approximately once a month, in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see section 4.4 and 4.8).

………

4.4   Special warnings and precautions for use

………

Injection technique

Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose monitoring is recommended after the change in the injection site, and dose adjustment of antidiabetic medications may be considered.

……….

4.8   Undesirable effects

………

Tabulated list of adverse reactions

The following related adverse reactions from clinical trials are listed below as MedDRA preferred term by system organ class and in order of decreasing incidence (very common: ≥ 1/10; common: ≥ 1/100 to < 1/10; uncommon: ≥ 1/1,000 to < 1/100; rare: ≥ 1/10,000 to < 1/1,000; very rare: < 1/10,000); not known (cannot be estimated form the available data).

Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

 

MedDRA system organ classes

Very common

Common

Uncommon

Rare

Very rare

Not known

Immune system disorders

 

Local allergy

 

X

 

 

 

 

Systemic allergy

 

 

 

X

 

 

Skin and subcutaneous tissue disorders

 

Lipodystrophy

 

 

X

 

 

 

Cutaneous amyloidosis

 

 

 

 

 

X

 

Description of selected adverse reactions

………

Skin and subcutaneous tissue disorders

Lipodystrophy and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (see section 4.4).

Lipodystrophy

Lipodystrophy at the injection site is uncommon.

 

10.          DATE OF REVISION OF THE TEXT

 

23 July 2020 03 September 2020

 

                                                                                                     HGL81M, HGL82M, HGL83M, HLG84

Updated on 2 September 2020 PIL

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - excipient warnings
  • Change to section 3 - dose and frequency
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - how to report a side effect
  • Change to section 5 - how to store or dispose
  • Change to section 6 - date of revision
  • Improved presentation of PIL

Free text change information supplied by the pharmaceutical company

Minor amendments to wording & formatting changes have been made throughout sections of the PIL.

Updated on 21 August 2020 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text
  • Improved presentation of SmPC

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Changes

 

The SmPC for Humalog 100 units/mL vial, cartridge, KwikPen, Junior KwikPen, Tempo Pen now includes new text relating to the non-marketed Tempo pen.

 

In addition, other minor formatting changes have been made throughout SmPC sections.

 Added (underline) deleted (strikethrough)

 

1.       NAME OF THE MEDICINAL PRODUCT

 Humalog 100 units/ml solution for injection in vial

Humalog 100 units/ml solution for injection in cartridge

Humalog 100 units/ml KwikPen solution for injection in a pre-filled pen

Humalog 100 units/ml Junior KwikPen solution for injection in a pre-filled pen

Humalog 100 units/ml Tempo Pen solution for injection in a pre-filled pen

 

2.       QUALITATIVE AND QUANTITATIVE COMPOSITION

………

 KwikPen and Tempo Pen

Each pre-filled pen contains 300 units of insulin lispro in 3 ml solution.

Each pre-filled pen KwikPen delivers 1-60 units in steps of 1 unit.

……… 

4.       CLINICAL PARTICULARS

 4.2   Posology and method of administration

Posology

The dosage dose should be determined by the physician, according to the requirement of the patient.

………

Humalog KwikPens

Humalog KwikPen is available in two strengths. The Humalog 100 units/ml KwikPen (and Humalog 200 units/ml KwikPen, see separate SmPC) delivers 1 – 60 units in steps of 1 unit in a single injection. The Humalog 100 units/ml Junior KwikPen delivers 0.5 – 30 units in steps of 0.5 units in a single injection. The number of insulin units is shown in the dose window of the pen regardless of strength and no dose conversion should be done when transferring a patient to a new strength or to a pen with a different dose step.

Humalog Tempo Pen

The Humalog 100 units/ml Tempo Pen delivers 1 – 60 units in steps of 1 unit in a single injection. The number of insulin units is shown in the dose window of the pen regardless of strength and no dose conversion should be done when transferring a patient to a new strength or to a pen with a different dose step. The Tempo Pen can be used with the optional transfer module Tempo Smart Button (see section 6.6).

As with any insulin injection, when using the Tempo Pen, Smart Button and the mobile application, the patient should be instructed to check their blood sugar levels when considering or making decisions about another injection if they are unsure how much they have injected.

………

4.4   Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered medicinal product should be clearly recorded.

……….

Tempo Pen

The Tempo Pen contains a magnet (see section 6.5) that may interfere with the functions of an implantable electronic medical device, such as a pacemaker. The magnetic field extends to approximately 1.5 cm.

……….

6.             PHARMACEUTICAL PARTICULARS

6.2       Incompatibilities

Vial

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

Cartridge, KwikPen, and Junior KwikPen and Tempo Pen

These medicinal products should not be mixed with any other insulin or any other medicinal product.

Vial

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

6.4       Special precautions for storage

……….

KwikPen, and Junior KwikPen and Tempo Pen

Store below 30°C. Do not refrigerate. The pre-filled pen should not be stored with the needle attached.

……….

6.5   Nature and contents of container

……….

Junior KwikPen

Type I glass cartridges, sealed with halobutyl disc seals secured with aluminium seals and bromobutyl plunger heads. Dimeticone or silicone emulsion may be used to treat the cartridge plunger. The 3 ml cartridges are sealed in a disposable pen injector, called the “Junior KwikPen”. Needles are not included.

3 ml Junior KwikPen: Packs of 1 pre-filled pen, 5 pre-filled pens or a multipack of 10 (2 packs of 5) pre-filled pens. Not all packs may be marketed.

Tempo Pen

Type I glass cartridges, sealed with halobutyl disc seals secured with aluminium seals and bromobutyl plunger heads. Dimeticone or silicone emulsion may be used to treat the cartridge plunger. The 3 ml cartridges are sealed in a disposable pen injector, called the “Tempo Pen”. The Tempo Pen contains a magnet (see section 4.4). Needles are not included.

3 ml Tempo Pen: Packs of 5 prefilled pens or a multipack of 10 (2 packs of 5) prefilled pens. Not all packs may be marketed.

6.6   Special precautions for disposal and other handling

……….

Humalog Tempo Pen

The Tempo Pen is designed to work with the Tempo Smart Button. The Tempo Smart Button is an optional product that can be attached to the Tempo Pen dose knob and aids in transmitting Humalog dose information from the Tempo Pen to a compatible mobile application. The Tempo Pen injects insulin with or without the Tempo Smart Button attached. To transmit data to the mobile application, follow the instructions provided with the Tempo Smart Button and the instructions with the mobile application.

 8.             MARKETING AUTHORISATION NUMBER(S)

……….

EU/1/96/007/046

EU/1/96/007/047

10.          DATE OF REVISION OF THE TEXT

13 January 2019 23 July 2020

 

 

HLG77M

Updated on 29 January 2020 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.4            Special warnings and precautions for use

 

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number

of the administered product should be clearly recorded.

 

 

4.8            Undesirable effects

 

Ireland: HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2, Tel: +353 1 6764971, Fax: +353 1 6762517, wWebsite: www.hpra.ie, e-mail: medsafety@hpra.ie, or United Kingdom: Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

 

10.      DATE OF REVISION OF THE TEXT

 

17 May  201816 January 2020

 

 

HLG69MHLG73M

Updated on 7 August 2019 SmPC

Reasons for updating

  • File format updated to PDF

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 5 July 2018 PIL

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - excipient warnings
  • Change to section 6 - date of revision

Updated on 29 June 2018 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text
  • Change from individual to joint SmPC

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

A major change in this variation is the consolidation of the 10 individual SmPCs (1 per presentation) into 4 combined SmPCs, divided as follows:

  • 100 u/ml cartridge, vial, KwikPen, Junior KwikPen
  • Mix25 100 u/ml cartridge, vial, KwikPen
  • Mix50 100 u/ml cartridge, KwikPen
  • 200 u/ml KwikPen

 

 

 

New information in SmPCs

  • All cartridges to be used in a Lilly reusable pen only
  • Clarification that vials only to be used for intravenous administration
  • 100 u/ml cartridges can be used in compatible pump systems for continuous subcutaneous insulin infusion (CSII)
  • New vial text in section 6.6: ‘Patients using vials must never share needles or syringes. The patient should discard the needle after every injection.’
  •  Insulin requirements in Renal/Hepatic impairment text – moved from section 4.4 (Special warnings and precautions for use) to 4.2 (Posology and method of administration)

Updated on 10 May 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 2 November 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 2 November 2017 PIL

Reasons for updating

  • Change to section 1 - what the product is used for
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 31 October 2017 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text
  • Change from joint to individual SPCs

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

changes from joint to individual SmPC

Changes

 

Added (underline) deleted (strikethrough)

 

 

4.2          Posology and method of administration

 

Paediatric population

Humalog can be used in adolescents and children (see section 5.1).

4.4          Special warnings and precautions for use

 

Humalog should only be used in children in preference to soluble insulin when a fast action of insulin might be beneficial. For example, in the timing of the injections in relation to meals.

4.8          Undesirable effects

 

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Ireland: HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2, Tel: +353 1 6764971, Fax: +353 1 6762517, website: www.hpra.ie, e-mail: medsafety@hpra.ie, or United Kingdom: Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

 

10. DATE OF REVISION OF THE TEXT

 

19th October 2017

 

HLG58M

Updated on 31 October 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 7 April 2017 SmPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Changes

6.             PHARMACEUTICAL PARTICULARS

6.5          Nature and contents of container and special equipment for use, administration or implantation

 

                ………..

5 x 3ml HUMALOG cartridges for a 3ml pen.

2 x (510 x 3ml) HUMALOG cartridges for a 3ml pen.

                ………..

 

 

8.             MARKETING AUTHORISATION NUMBERS

                ………..

                HUMALOG cartridges

              5 x 3ml HUMALOG cartridges for a 3ml pen:               EU/1/96/007/004

              2 x (510 x 3ml) HUMALOG cartridges for a 3ml pen:   EU/1/96/007/023

                …………

 

 

10.          DATE OF REVISION OF THE TEXT

 

10 November 2016     17 March 2017

Updated on 5 December 2016 PIL

Reasons for updating

  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - date of revision
  • Change to name of medicinal product

Updated on 1 December 2016 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.5 - Nature and contents of container
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

(New text bold.  Text struck-through removed)

 

 

Changes

Throughout SPC, the abbreviated term for units, ‘U’, is replaced with the full spelling (i.e.- ‘units’). 

 

 

10.          DATE OF REVISION OF THE TEXT

 

01 January 2016   10 November 2016

Updated on 19 January 2016 PIL

Reasons for updating

  • Change to further information section
  • Change to date of revision
  • Change to MA holder contact details
  • Addition of information on reporting a side effect.

Updated on 18 January 2016 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

(New text bold.  Text struck-through removed)

 

 

Changes

 

4.             CLINICAL PARTICULARS

4.4         Special warnings and precautions for use

 

……………

 

Combination of Humalog with pioglitazone:

Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and Humalog is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.

 

Instructions for use and handling

Cartridge: To prevent the possible transmission of disease, each cartridge must be used by one patient only, even if the needle on the delivery device is changed.

 

KwikPen: To prevent the possible transmission of disease, each pen must be used by one patient only, even if the needle is changed.

 

 

4.8         Undesirable effects

 

                ……………..

 

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via UK: www.mhra.gov.uk/yellowcard, or Ireland: IMB Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2, Tel: +353 1 6764971, Fax: +353 1 6762517, www.imb.ie, imbpharmacovigilance@imb.ie.  Ireland: HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2, Tel: +353 1 6764971, Fax: +353 1 6762517, website: www.hpra.ie, e-mail: medsafety@hpra.ie., or the UK: Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard.

 

 

6.             PHARMACEUTICAL PARTICULARS

6.6          Special precautions for disposal and other handling

 

                ……………..

 

HUMALOG cartridges

 

Instructions for use and handling

To prevent the possible transmission of disease, each cartridge must be used by one patient only, even if the needle on the delivery device is changed.

               

 

                …………….

               

HUMALOG KwikPen

 

Instructions for use and handling

To prevent the possible transmission of disease, each pen must be used by one patient only, even if the needle is changed.

 

7.            MARKETING AUTHORISATION HOLDER

 

Eli Lilly Nederland B.V.

Papendorpseweg 83, 3528 BJ Utrecht Grootslag 1-5, NL-3991 RA, Houten
The Netherlands

 

 

10.          DATE OF REVISION OF THE TEXT

 

14 November 2013          01 January 2016

 

 

 

Updated on 1 July 2014 PIL

Reasons for updating

  • Change of manufacturer
  • Change to date of revision

Updated on 9 May 2014 PIL

Reasons for updating

  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 2 May 2014 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.      CLINICAL PARTICULARS

 

4.2                   Posology and method of administration

 

                         . . . .

 

HUMALOG can be used in conjunction with a longer-acting human insulin or oral sulphonylurea agents, on the advice of a physician.

 

Use of HUMALOG in an insulin infusion pump:

Only certain CE-marked insulin infusion pumps may be used to infuse insulin lispro. Before infusing insulin lispro, the manufacturer’s instructions should be studied to ascertain the suitability or otherwise for the particular pump. Read and follow the instructions that accompany the infusion pump. Use the correct reservoir and catheter for the pump. The infusion set (tubing and cannula) should be changed in accordance with the instructions in the product information supplied with the infusion set. Change the infusion set every 48 hours. Use aseptic technique when inserting the infusion set. In the event of a hypoglycaemic episode, the infusion should be stopped until the episode is resolved. If repeated or severe low blood glucose levels occur, notify your health care professional and consider the need to reduce or stop your insulin infusion. A pump malfunction or obstruction of the infusion set can result in a rapid rise in glucose levels. If an interruption to insulin flow is suspected, follow the instructions in the product literature and if appropriate, notify your health care professional. When used with an insulin infusion pump, HUMALOG should not be mixed with any other insulin.

 

                        . . . .

 

4.8                   Undesirable effects 

. . . .

 

            Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via UK: www.mhra.gov.uk/yellowcard, or Ireland: IMB Pharmacovigilance, Section, Irish Medicines Board, Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace, IRL - Dublin 2, Tel: +353 1 6764971, Fax: +353 1 6762517, www.imb.ie, imbpharmacovigilance@imb.ie.

 

 

10.          DATE OF REVISION OF THE TEXT

 

            Revision date changed to:
            23 April 2014

Updated on 30 November 2013 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.             CLINICAL PARTICULARS

 

4.8                          Undesirable effects

Hypoglycaemia is the most frequent undesirable effect of insulin therapy that a patient with diabetes may suffer.  Severe hypoglycaemia may lead to loss of consciousness and in extreme cases, death. No specific frequency for hypoglycaemia is presented, since hypoglycaemia is a result of both the insulin dose and other factors, e.g., a patient’s level of diet and exercise.

Local allergy in patients is common (1/100 to <1/10). Redness, swelling, and itching can occur at the site of insulin injection. This condition usually resolves in a few days to a few weeks. In some instances, this condition may be related to factors other than insulin, such as irritants in the skin cleansing agent or poor injection technique. Systemic allergy, which is rare (1/10,000 to <1/1,000) but potentially more serious, is a generalised allergy to insulin. It may cause a rash over the whole body, shortness of breath, wheezing, reduction in blood pressure, fast pulse, or sweating.  Severe cases of generalised allergy may be life-threatening.

Lipodystrophy at the injection site is uncommon (1/1,000 to <1/100).

Cases of oedema have been reported with insulin therapy, particularly if previous poor metabolic control is improved by intensified insulin therapy.

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via UK: www.mhra.gov.uk/yellowcard, or Ireland: Pharmacovigilance Section, Irish Medicines Board, Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace, IRL - Dublin 2, Tel: +353 1 6764971, Fax: +353 1 6762517, www.imb.ie, imbpharmacovigilance@imb.ie.

 

 

10.          DATE OF REVISION OF THE TEXT

 

Revision date changed to:
14 November 2013

 

 

 

Updated on 27 November 2013 PIL

Reasons for updating

  • Change to date of revision
  • Change to improve clarity and readability
  • Addition of information on reporting a side effect.

Updated on 3 October 2013 PIL

Reasons for updating

  • Change to further information section
  • Change to date of revision

Updated on 16 May 2012 SmPC

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Changes


6.             PHARMACEUTICAL PARTICULARS


6.3          Shelf-life

 

Unopened vials


2 years
  3 years

 

 

10.          DATE OF REVISION OF THE TEXT

 

Revision date changed to:

 

 

13 April 2012

Updated on 13 May 2011 PIL

Reasons for updating

  • Change to side-effects
  • Change to further information section
  • Change to date of revision

Updated on 12 May 2011 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

PLEASE NOTE:  the SPC has been updated throughout in order to reflect QRD template changes and the removal of Humalog Pen information.

 

Changes

 

4.             CLINICAL PARTICULARS

 

4.8          Undesirable effects

 

Added (new) text:

 

Cases of oedema have been reported with insulin therapy, particularly if previous poor metabolic control is improved by intensified insulin therapy.

 

10.          DATE OF REVISION OF THE TEXT

 

Revision date changed to:

  

18 April 2011

Updated on 8 March 2011 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to date of revision

Updated on 7 March 2011 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Added (new) text:

 

Changes

 

4.             CLINICAL PARTICULARS

 

4.4          Special warnings and precautions for use

 

Combination of Humalog with pioglitazone:

Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and Humalog is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.

 

 

 

10.          DATE OF REVISION OF THE TEXT

 

Revision date changed to.

 

 

17 February 2011

 

 

 

OTHER CHANGE:

 

Individual affiliate contact details deleted from SPC consistent with other European SPCs.

 

Updated on 3 August 2009 PIL

Reasons for updating

  • Change to date of revision
  • Change to storage instructions
  • Change to further information section

Updated on 14 July 2009 SmPC

Reasons for updating

  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company



4.             CLINICAL PARTICULARS

4.5          Interaction with other medicinal products and other forms of interaction

 

Added (bold):

 

Insulin requirements may be reduced in the presence of medicinal products with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulpha antibiotics, certain antidepressants (monoamine oxidase inhibitors, selective serotonin reuptake inhibitors),

 

 

 

6.             PHARMACEUTICAL PARTICULARS

 

6.3          Shelflife

 

Added:

 

Unopened vials

 

2 years

 

Unused cartridges and unused pre-filled pens

 

Added (bold) Deleted (strikethrough):

 

3 years 2 years

 

Added:

 

After cartridge insertion, or after first use (vial and prefilled pen)

 

Added (bold) deleted (strikethrough):

 

After cartridge insertion, or after first use (vial and prefilled pen) insertion of the cartridge in a pen, or the first use of the vial or prefilled pen, the solution should be used within 28 days. when stored below 30°C.

 

6.4          Special precautions for storage

 

Added:

 

Unused cartridge and unused pre-filled pens

 

Store in a refrigerator (2°C-8°C).  Do not freeze.  Do not expose to excessive heat or direct sunlight.

 

Added:

 

Unopened vials

Store in a refrigerator (2°C - 8°C).

 

After first use (vials only)

Store in a refrigerator (2°C - 8°C) or below 30°C.

 

After cartridge insertion or first use (pre-filled pen)

Store below 30°C. Do not refrigerate. The pen with the inserted cartridge and the pre-filled pen should not be stored with the needle attached.

 

6.6                Special precautions for disposal and other handling

 

Section re-formatted to provide better clarity between the pen and Kwikpen instructions.

 

 

 

9.             DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

 

Dates changed as per EMEA request:

 

Date of first authorisation:        30 April 1996

 

Date of last renewal:                   30 April 2006

 

 

 

10.          DATE OF REVISION OF THE TEXT

 

01 July 2009

Updated on 3 June 2008 SmPC

Reasons for updating

  • Change to marketing authorisation holder address

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Addition:

This SPC has been revised in its entirety adding Humalog KwikPen text throughout – there are no other content

changes.

10. DATE OF REVISION OF THE TEXT

31 January 2008

Updated on 27 February 2008 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.       CLINICAL PARTICULARS

 

4.2          Posology and method of administration

 

 

Re-Formatted:

 

Use of HUMALOG in an insulin infusion pump:

Only certain CE-marked insulin infusion pumps may be used to infuse insulin lispro. Before infusing insulin lispro, the manufacturers instructions should be studied to ascertain the suitability or otherwise for the particular pump. Read and follow the instructions that accompany the infusion pump. Use the correct reservoir and catheter for the pump. Change the infusion set every 48 hours. Use aseptic technique when inserting the infusion set. In the event of a hypoglycaemic episode, the infusion should be stopped until the episode is resolved. If repeated or severe low blood glucose levels occur, notify your health care professional and consider the need to reduce or stop your insulin infusion. A pump malfunction or obstruction of the infusion set can result in a rapid rise in glucose levels. If an interruption to insulin flow is suspected, follow the instructions in the product literature and if appropriate, notify your health care professional. When used with an insulin infusion pump, HUMALOG should not be mixed with any other insulin.

 

Intravenous administration of insulin:

Intravenous injection of insulin lispro should be carried out following normal clinical practise for intravenous injections, for example by an intravenous bolus or by an infusion system. Frequent monitoring of the blood glucose levels is required.

Infusion systems at concentrations from 0.1U/ml to 1.0U/ml insulin lispro in 0.9% sodium chloride or 5% dextrose are stable at room temperature for 48 hours. It is recommended that the system is primed before starting the infusion to the patient.

 

 

 

6.             PHARMACEUTICAL PARTICULARS

 

6.6          Special precautions for disposal and other handling

 

 

Deleted from section 4.2 and inserted into section 6.6:

 

 

Instructions for Use and Handling

 

Humalog vials

 

The vial is to be used in conjunction with an appropriate syringe (100U markings).

 

a)            Preparing a dose

 

Inspect the Humalog solution.  It should be clear and colourless.  Do not use Humalog if it appears cloudy, thickened, or slightly coloured, or if solid particles are visible.

 

i)             Humalog

 

1.             Wash your hands.

 

2.             If using a new vial, flip off the plastic protective cap, but do not remove the stopper.

 

3.             If the therapeutic regimen requires the injection of basal insulin and Humalog at the same time, the two can be mixed in the syringe.  If mixing insulins, refer to the instructions for mixing that follow in section ii) and 6.2.

 

4.             Draw air into the syringe equal to the prescribed Humalog dose.  Wipe the top of the vial with an alcohol swab.  Put the needle through the rubber top of the Humalog vial and inject the air into the vial.

 

5.             Turn the vial and syringe upside down.  Hold the vial and syringe firmly in one hand.

 

6.             Making sure the tip of the needle is in the Humalog, withdraw the correct dose into the syringe.

 

7.             Before removing the needle from the vial, check the syringe for air bubbles that reduce the amount of Humalog in it.  If bubbles are present, hold the syringe straight up and tap its side until the bubbles float to the top.  Push them out with the plunger and withdraw the correct dose.

 

8.             Remove the needle from the vial and lay the syringe down so that the needle does not touch anything.

 

ii)            Mixing Humalog with longer-acting human insulins (see section 6.2)

 

1.                   Humalog should be mixed with longer-acting human insulins only on the advice of a doctor.

 

2.             Draw air into the syringe equal to the amount of longer-acting insulin being taken.  Insert the needle into the longer-acting insulin vial and inject the air.  Withdraw the needle.

 

3.             Now inject air into the Humalog vial in the same manner, but do not withdraw the needle.

 

4.             Turn the vial and syringe upside down.

 

5.             Making sure the tip of the needle is in the Humalog, withdraw the correct dose of Humalog into the syringe.

 

6.             Before removing the needle from the vial, check the syringe for air bubbles that reduce the amount of Humalog in it.  If bubbles are present, hold the syringe straight up and tap its side until the bubbles float to the top.  Push them out with the plunger and withdraw the correct dose.

 

7.             Remove the needle from the vial of Humalog and insert it into the vial of the longer-acting insulin.  Turn the vial and syringe upside down.  Hold the vial and syringe firmly in one hand and shake gently.  Making sure the tip of the needle is in the insulin, withdraw the dose of longer-acting insulin.

 

8.             Withdraw the needle and lay the syringe down so that the needle does not touch anything.

 

b)            Injecting a dose

 

1.                   Choose a site for injection.

 

2.             Clean the skin as instructed.

 

3.             Stabilise the skin by spreading it or pinching up a large area.  Insert the needle and inject as instructed.

 

4.             Pull the needle out and apply gentle pressure over the injection site for several seconds.  Do not rub the area.

 

5.             Dispose of the syringe and needle safely.

 

6.             Use of the injection sites should be rotated so that the same is not used more than approximately once a month.

 

c)             Mixing insulins

 

Do not mix insulin in vials with insulin in cartridges.  See section 6.2.

 

Humalog cartridges

 

Humalog cartridges are to be used with a CE marked pen as recommended in the information provided by the device manufacturer.

 

a)            Preparing a dose

 

Inspect the Humalog solution.  It should be clear and colourless.  Do not use Humalog if it appears cloudy, thickened, or slightly coloured, or if solid particles are visible.

 

The following is a general description.  The manufacturer’s instructions with each individual pen must be followed for loading the cartridge, attaching the needle, and administering the insulin injection.

 

b)            Injecting a dose

 

1.             Wash your hands.

 

2.                   Choose a site for injection.

 

3.             Clean the skin as instructed.

 

4.             Remove outer needle cap.

 

5.             Stabilise the skin by spreading it or pinching up a large area.  Insert the needle as instructed.

 

6.             Press the knob.

 

7.             Pull the needle out and apply gentle pressure over the injection site for several seconds.  Do not rub the area.

 

8.             Using the outer needle cap, unscrew the needle and dispose of it safely.

 

9.                   Use of injection sites should be rotated so that the same site is not used more than approximately once a month.

 

c)             Mixing insulins

 

Do not mix insulin in vials with insulin in cartridges.  See section 6.2.

 

Humalog Pens

 

a)            Preparing a dose

 

1.             Inspect the Humalog Pen solution.

 

It should be clear and colourless.  Do not use Humalog Pen if it appears cloudy, thickened, or slightly coloured, or if solid particles are visible.

 

2.             Put on the needle.

 

Wipe the rubber seal with alcohol.  Remove the paper tab from the capped needle.  Screw the capped needle clockwise onto the pen until it is tight.  Hold the pen with needle pointing up and remove the outer needle cap and inner needle cover.

 

3.             Priming the pen (check insulin flow).

 

(a)           The arrow should be visible in the dose window.  If the arrow is not present, turn the dose knob clockwise until the arrow appears and notch is felt or visually aligned.

 

(b)           Pull dose knob out (in direction of the arrow) until a ‘0’ appears in the dose window.  A dose cannot be dialled until the dose knob is pulled out.

 

(c)           Turn dose knob clockwise until a ‘2’ appears in the dose window.

 

(d)           Hold the pen with needle pointing up and tap the clear cartridge holder gently with your finger so any air bubbles collect near the top.  Depress the injection button fully until you feel or hear a click.  You should see a drop of insulin at the tip of the needle.  If insulin does not appear, repeat the procedure until insulin appears.

 

(e)           Always prime the pen (check the insulin flow) before each injection.  Failure to prime the pen may result in an inaccurate dose.

 

4.             Setting the dose.

 

(a)           Turn the dose knob clockwise until the arrow appears in the dose window and a notch is felt or visually aligned.

 

(b)           Pull the dose knob out (in the direction of the arrow) until a ‘0’ appears in the dose window.  A dose cannot be dialled until the dose knob is pulled out.

 

(c)           Turn the dose knob clockwise until the dose appears in the dose window.  If too high a dose is dialled, turn the dose knob backward (anti-clockwise) until the correct dose appears in the window.  A dose greater than the number of units remaining in the cartridge cannot be dialled.

 

b)            Injecting a dose

 

1.             Wash your hands.

 

2.             Choose a site for injection.

 

3.             Clean the skin as instructed.

 

4.             Remove outer needle cap.

 

5.             Stabilise the skin by spreading it or pinching up a large area.  Insert the needle as instructed.

 

6.             Press the injection button down with the thumb (until you hear or feel a click); wait 5 seconds.

 

7.             Pull the needle out and apply gentle pressure over the injection site for several seconds.  Do not rub the area.

 

8.             Immediately after an injection, use the outer needle cap to unscrew the needle.  Remove the needle from the pen.  This will ensure sterility, and prevent leakage, re-entry of air, and potential needle clogs.  Do not reuse the needle.  Dispose of the needle in a responsible manner.  Needles and pens must not be shared.

 

The prefilled pen can be used until it is empty.  Please properly discard or recycle.

 

9.             Replace the cap on the pen.

 

10.          Use of injection sites should be rotated so that the same site is not used more than approximately once a month.

 

11.          The injection button should be fully depressed before using the pen again.

 

c)             Mixing insulins

 

Do not mix insulin in vials with insulin in cartridges.  See section 6.2.

 

 

 

 

 

10.          DATE OF REVISION OF THE TEXT

 

31 January 2008

 

Updated on 13 June 2007 PIL

Reasons for updating

  • Change to drug interactions
  • Change to date of revision

Updated on 29 May 2007 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.             CLINICAL PARTICULARS

 

4.4          Special warnings and precautions for use

 

Added text in bold

 

Transferring a patient to another type or brand of insulin should be done under strict medical supervision.  Changes in strength, brand (manufacturer), type (soluble, isophane, lente, etc), species (animal, human, human insulin analogue), and/or method of manufacture (recombinant DNA versus animal-source insulin) may result in the need for a change in dosage.  For fast-acting insulins, any patient also on basal insulin must optimise dosage of both insulins to obtain glucose control across the whole day, particularly nocturnal/fasting glucose control.

 

4.5          Interaction with other medicinal products and other forms of interaction

 

Added text in bold

 

Insulin requirements may be reduced in the presence of medicinal products with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulpha antibiotics, certain antidepressants (monoamine oxidase inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta-blockers, octreotide, or alcohol.

 

 

 

5.             PHARMACOLOGICAL PROPERTIES

 

5.1          Pharmacodynamic properties

 

Deletions in strikethrough text

 

Clinical trials in patients with Type 1 and Type 2 diabetes have demonstrated reduced postprandial hyperglycaemia with insulin lispro compared to soluble human insulin.  For fast-acting insulins, any patient also on a basal insulin must optimise dosage of both insulins to obtain improved glucose control across the whole day.

 

 

 

10.          DATE OF REVISION OF THE TEXT

 

New date

 

3 May 2007

Updated on 26 September 2006 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 8 - MA number
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.             CLINICAL PARTICULARS

 

4.2                Posology and method of administration

 

Text previously under the heading ‘Instructions for use, handling and disposal’ (section 6.6), now appears unchanged here.

 

4.8                Undesirable effects

 

Added:

 

No specific frequency for hypoglycaemia is presented, since hypoglycaemia is a result of both the insulin dose and other factors, eg, a patient’s level of diet and exercise.

 

Reworded:

 

Local allergy in patients is common (1/100 to <1/10).  Redness, swelling, and itching can occur at the site of insulin injection.  This condition usually resolves in a few days to a few weeks.  In some instances, this condition may be related to factors other than insulin, such as irritants in the skin cleansing agent or poor injection technique.  Systemic allergy, which is rare (1/10,000 to <1/1,000) but potentially more serious, is a generalised allergy to insulin.  It may cause a rash over the whole body, shortness of breath, wheezing, reduction in blood pressure, fast pulse, or sweating.  Severe cases of generalised allergy may be life-threatening.

 

Lipodystrophy at the injection site is uncommon (1/1,000 to <1/100).

 

6.             PHARMACEUTICAL PARTICULARS

 

6.5          Nature and contents of container

 

Added:

 

2 x 10ml Humalog vials.

5 x (1 x 10ml) Humalog vials.

 

2 x (5 x 3ml) Humalog cartridges for a 3ml pen.

 

2 x (5 x 3ml) Humalog Pens.

 

6.6          Special precautions for disposal

 

Added:

 

Any unused product or waste material should be disposed of in accordance with local requirements.

 

8.             MARKETING AUTHORISATION NUMBERS

 

Added:

 

Humalog vials

2 x 10ml Humalog vials:                   EU/1/96/007/020

5 x (1 x 10ml) Humalog vials:           EU/1/96/007/021


 

 

Humalog cartridges

2 x (5 x 3ml) Humalog cartridges for a 3ml pen:     EU/1/96/007/023

 

Humalog Pens

2 x (5 x 3ml) Humalog Pens:     EU/1/96/007/026

 

9.             DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

 

Date of first authorisation:                         Vial:                                30 April 1996

                                                                        3ml cartridge:                30 April 1996

                                                                        Humalog Pen 3ml:        30 April 1996

 

Date of renewal of the authorisation:       Vial:                                30 April 2006

                                                                        3ml cartridge:                30 April 2006

                                                                        Humalog Pen 3ml:        30 April 2006

 

10.          DATE OF REVISION OF THE TEXT

 

9 February 2006

 

Updated on 10 July 2006 PIL

Reasons for updating

  • Change to date of revision

Updated on 14 September 2004 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 26 January 2004 SmPC

Reasons for updating

  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 16 October 2003 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)